###### Key messages

What is already known about this subject?
=========================================

-   Metabolic disturbances such as obesity or diabetes mellitus are associated with osteoarthritis (OA), but data about the link between OA and lipid disturbances remain conflicting.

What does this study add?
=========================

-   This is the first systematic review and meta-analysis demonstrating an association between OA and dyslipidemia. This result reinforces the concept of the metabolic syndrome-associated OA phenotype.

How might this impact on clinical practice?
===========================================

-   This study emphasises the need to screen and manage cardiovascular comorbidities, especially lipid disturbances in patients with OA in clinical daily practice.

Introduction {#s1}
============

Osteoarthritis (OA) is the most common joint disease and a major cause of pain and disability. It is currently considered a disease with multiple distinguishable phenotypes: post-traumatic, ageing-related, genetic and metabolic syndrome (MetS)-associated OA.[@R1] Metabolic OA, the most commonly studied phenotype, is defined by the association between OA and MetS, associating obesity, hyperglycaemia with insulin resistance, dyslipidemia and hypertension.[@R2] Metabolic OA mainly affects middle-aged people (45--65 years) and leads to knee, hand and generalised OA. The association between OA and MetS has been reported in several epidemiological studies.[@R3] The pathophysiological link between both diseases could be chronic low-grade systemic inflammation occurring in both conditions.[@R5]

The association of OA with each MetS component has been investigated.[@R6] Obesity and overweight are independently linked to hand OA, with a twofold increased risk.[@R7] This association suggests the release of inflammatory mediators by adipose tissue adipokines. We recently reported an association between OA and diabetes mellitus, with a 1.46-fold increased risk of OA with diabetes mellitus and a 1.41-fold increased risk of diabetes mellitus with OA.[@R8] The link between both pathologies could be explained by the action of pro-inflammatory cytokines and oxidative stress occurring in both diseases.[@R9]

The link between OA and the other components of MetS remains debated. Experimental studies have suggested that lipid disturbances could be involved in OA pathophysiology,[@R13] but epidemiological studies revealed heterogeneous results.

With a systematic literature review and meta-analysis, we aimed to investigate the prevalence of dyslipidemia in patients with OA and assess whether OA and dyslipidemia are associated.

Methods {#s2}
=======

The systematic review was registered on PROSPERO (CRD: 42016037290).

Literature search {#s2a}
-----------------

We performed a systematic search of articles in MEDLINE via PubMed, EMBASE and the Cochrane library. The keywords used for the PubMed search were ((('Dyslipidemias'\[Mesh\] OR 'Hypertriglyceridemia'\[Mesh\]) OR 'Hypercholesterolemia'\[Mesh\]) OR 'HDL'\[All Fields\] OR 'LDL'\[All Fields\] OR 'Triglycerides'\[All Fields\] OR 'Hyperlipidemias'\[Mesh\]) OR 'Cholesterol'\[Mesh\] OR 'Metabolic Syndrome X'\[Mesh\] AND 'Osteoarthritis'\[Mesh\] AND ('humans'\[MeSH Terms\] AND (English\[lang\] OR French\[lang\])). No time limit was set for publication date, and articles published up to 1 January 2016 were searched. We also searched the abstracts from international meetings of the American College of Rheumatology (ACR), European League Against Rheumatism, Société Française de Rhumatologie, European Society of Cardiology, Endocrine Society's Annual Meeting and European Congress of Endocrinology.

Study selection {#s2b}
---------------

We selected articles published in English or French that described observational studies of adults (\>18 years of age) with cohort, case--control and cross-sectional designs. Studies were included if they specified the number of patients with OA and dyslipidemia and/or the prevalence or incidence of OA in patients with dyslipidemia and/or dyslipidemia in patients with OA, and/or the mean values of parameters of dyslipidemia in patients with and without OA and/or the existence or not of an association between OA and dyslipidemia. We excluded non-observational studies (therapeutic trials, reviews, letters and case reports). Articles that did not mention the number of patients with OA or dyslipidemia and those that did not evaluate the link between the two diseases were excluded. The selection of articles was based on titles and abstracts, then full texts.

Data synthesis {#s2c}
--------------

We extracted the following data: publication data (title of the article, first author, journal and publication date), study design (type of study, year(s) of inclusion, study quality score), population (total number of patients included, mean age and sex of patients), methodology of articles (the definition used for OA and dyslipidemia, OA location) and data needed for statistical analysis (number of patients with OA and/or dyslipidemic patients; mean total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglyceride (TG) levels (mg/dL or mmol/L); and number of patients receiving statins, number with MetS and number with obesity or mean body mass index (BMI) in kg/cm^2^). The quality of the study was estimated by using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) scale, the score expressed in percentage of positive answers in relation to the number of items selected.[@R14]

Statistical analysis {#s2d}
--------------------

First, we performed a descriptive analysis of the prevalence of dyslipidemia in patients with and without OA and used the number of patients with dyslipidemia and total number with and without OA. To estimate this prevalence from cohort longitudinal prospective studies, we used baseline data. Prevalence was expressed as mean±SD Second, we calculated the mean TC, LDL, HDL and TG levels in patients with and without OA. Third, for studies examining an association between OA and dyslipidemia, we calculated the risk of dyslipidemia with OA by estimating the overall OR with 95% CIs. The data were extracted from studies examining the number of dyslipidemic patients with and without OA. We used Revman V.5.3 for the meta-analysis with a fixed-effects model. Heterogeneity was assessed by the I² index; with I²\>50% (high heterogeneity), we used a random-effects model, and with I^2^ \<50% (low heterogeneity), we used a fixed-effects model. With strong heterogeneity, we used a randomised-effects analysis. To investigate potential publication bias, we have performed the funnel plot. The association was considered positive with OR \>1, and the result was considered statistically significant with p≤0.05. We performed sensitivity and subgroup analyses.

Results {#s3}
=======

Characteristics of studies included {#s3a}
-----------------------------------

The selection of articles is reported in the flow chart ([figure 1](#F1){ref-type="fig"}). We identified 605 publications; 48 articles (including 13 abstracts) from 43 studies were included (2 articles from the SEKOIA study, 4 from the FRAMINGHAM study and 2 from the National Health and Nutrition Examination Survey III). One abstract[@R15] was obtained from the EMBASE database and not from screening congress abstracts. The 48 articles described 29 cross-sectional, 10 cohort and 9 case--control studies. Among them, 29 articles involved the OA population and 19 the general population ([table 1](#T1){ref-type="table"}). We did not find any studies based on a cohort of patients with dyslipidemia, which explains why the prevalence or relative risk of OA in patients with dyslipidemia was not calculated. [Table 2](#T2){ref-type="table"} shows the definitions of OA and dyslipidemia in selected studies.

![Flow chart of articles in the study](rmdopen-2017-000442f01){#F1}

###### 

Description of the 48 articles studies selected for analysis

  Osteoarthritis population                                         General population                              
  --------------------------- ------------------------------------- -------------------- -------------------------- ------
  Cross-selectional           Stürmer *et al*[@R25]                 1998                 Davis *et al*[@R26]        1988
                              Racaza *et al*[@R65]                  2012                 Han *et al*[@R27]          2013
                              Erb *et al*[@R66]                     2004                 Dahaghin *et al*[@R41]     2007
                              Eymard *et al*[@R28]                  2015                 Haugen *et al*[@R42]       2015
                              Shea *et al*[@R29]                    2015                 Inoue *et al*[@R30]        2011
                              Salamon *et al*[@R50]                 2015                 Cemeroglu *et al*[@R22]    2014
                              Abourazzak *et al*[@R20]              2015                 Meek *et al*[@R51]         2014
                              Juge *et al*[@R17]*\**                2015                 Al-Arfaj[@R31]             2003
                              Rollefstad *et al*[@R23]*\**          2014                 Suri *et al*[@R48]         2010
                              Saunders *et al*[@R53]*\**            2013                 Puenpatom *et al*[@R4]     2009
                              Nuñez *et al*[@R32]*\**               2012                 Hart *et al*[@R19]         1995
                              Shukurova *et al*[@R67]*\**           2014                 Maddah *et al*[@R24]       2015
                              Salaru *et al*[@R33]*\**              2013                 Engström *et al*[@R34]     2009
                              Kemta Lekpa *et al*[@R35]*\**         2014                 Yoshimura *et al*[@R3]     2012
                              Niu *et al*[@R36]*\**                 2015                 Nielen *et al*[@R54]       2012
                              Haugen *et al*[@R43]*\**              2013                 Marshall *et al*[@R44]     2015
                              Courties *et al*[@R45]*\**            2014                 Hussain *et al*[@R37]      2014
  Cohort                      Gandhi *et al*[@R49]                  2014                 Sowers *et al*[@R21]       2009
                              Laires *et al*[@R38]*\**              2015                 Massengale *et al*[@R46]   2012
                              Thelier--Deloison *et al*[@R15]*\**   2012                                            
  Case--control               Soran *et al*[@R16]                   2008                                            
                              Cheras *et al*[@R18]                  1997                                            
                              Mishra *et al*[@R39]                  2012                                            
                              Oliviero *et al*[@R52]                2012                                            
                              Addimanda *et al*[@R47]               2012                                            
                              Philbin *et al*[@R55]                 1996                                            
                              Irshad *et al*[@R56]                  2014                                            
                              Zayed *et al*[@R40]                   2013                                            
                              Cheng *et al*[@R57]*\**               2013                                            

\*Data from a congress.

###### 

Characteristics of the 48 included articles: definitions of osteoarthritis (OA) and dyslipidemia, outcomes and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study quality

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                OA definition                            Dyslipidemia definition                                                     Outcome                               STROBE study quality (%)
  ------------------------------------- ---------------------------------------- --------------------------------------------------------------------------- ------------------------------------- --------------------------
  Stürmer *et al*[@R25]                 Arthroplasty or KL≥2                     TC≥240 mg/dL and/or statin therapy                                          MV in OA+\                            53
                                                                                                                                                             Association of OA and dyslipidemia    

  Racaza *et al*[@R65]                  ACR or Cq and Rx                         --                                                                          NPD in OA+                            42

  Erb *et al*[@R66]                     Cq and Rx                                --                                                                          MV in OA+                             50

  Eymard *et al*[@R28]                  ACR Cq and Rx\                           History of dyslipidemia                                                     NPD in OA+                            82
                                        KL scale                                                                                                                                                   

  Shea *et al*[@R29]                    Cq and Rx                                --                                                                          NPS in OA+\                           78
                                                                                                                                                             MV in OA+                             

  Salamon *et al*[@R50]                 ACR                                      --                                                                          NPD in OA+\                           72
                                                                                                                                                             MV in OA+                             

  Abourazzak *et al*[@R20]              KL≥2                                     HDL\<50 mg/dL\                                                              NPD in OA+                            66
                                                                                 TG≥150 mg/dL                                                                                                      

  Juge *et al*[@R17]*\**                Rx                                       --                                                                          NPD in OA+                            NA

  Rollefstad *et al*[@R23]*\**          History of OA                            --                                                                          MV in OA+ and OA--\                   NA
                                                                                                                                                             Association of OA and dyslipidemia    

  Saunders *et al*[@R53]*\**            KL scale                                 TC\>4 mmol/L                                                                NPD in OA+\                           NA
                                                                                                                                                             Association of MV and KL scale        

  Nuñez *et al*[@R32]*\**               --                                       Hypercholesterolemia (ND)                                                   NPD in OA+                            NA

  Shukurova *et al*[@R67]*\**           \-                                       Hypercholesterolemia (ND)                                                   NPD in OA+                            NA

  Salaru *et al*[@R33]*\**              ACR                                      --                                                                          NPD in OA+                            NA

  Kemta Lekpa *et al*[@R35]\*           ACR                                      --                                                                          NPD in OA+                            NA

  Niu *et al*[@R36]*\**                 Arthroplasty or KL≥2                     HDL\<40 mg/dL in M;\<50 mg/dL in W\                                         Association of OA and dyslipidemia    NA
                                                                                 TG\>150 mg/dL                                                                                                     

  Haugen *et al*[@R43]*\**              KL≥2                                     Low HDL and HTG (ND)                                                        NPD in OA+\                           NA
                                                                                                                                                             Association of OA and dyslipidemia    

  Courties *et al*[@R45]*\**            KL≥2                                     --                                                                          NPD in OA+                            NA

  Gandhi *et al*[@R49]                  Cq and Rx                                HDL\<35 mg/dL in M,\<40 mg/dL in W; TG≥150 mg/dL                            NPD in OA+                            52

  Laires *et al*[@R38]*\**              --                                       --                                                                          NPD in OA+                            NA

  Thelier--Deloison *et al*[@R15]*\**   History of OA                            --                                                                          NPD in OA+ and OA--\                  NA
                                                                                                                                                             Association of OA and dyslipidemia    

  Soran *et al*[@R16]                   Cq and Rx                                --                                                                          MV in OA+ and OA--\                   65
                                                                                                                                                             Association of OA and dyslipidemia    

  Cheras *et al*[@R18]                  Cq and Rx                                --                                                                          MV in OA+ and OA--\                   75
                                                                                                                                                             Association of OA and dyslipidemia    

  Mishra *et al*[@R39]                  KL scale\                                --                                                                          MV in OA+ and OA--\                   58
                                        ACR                                                                                                                  Association of OA and dyslipidemia    

  Oliviero *et al*[@R52]                ACR                                      --                                                                          MV in OA+ and OA--\                   67
                                                                                                                                                             Association OA and dyslipidemia       

  Addimanda *et al*[@R47]               Cq\                                      LDL≥130 mg/dL and/or CT≥240 mg/dL and/or statin therapy                     NPD in OA+ and OA--\                  75
                                        KL scale                                                                                                             Association of OA and dyslipidemia    

  Philbin *et al*[@R55]                 Questionnaire\                           LDL≥160 mg/dL and/or HDL≤35 mg/dL                                           NPD in OA+ and OA--\                  73
                                        Radiological Danielson scale                                                                                         NPS in OA+ and OA--\                  
                                                                                                                                                             Association of OA and dyslipidemia\   
                                                                                                                                                             MV in OA+ and OA--                    

  Irshad *et al*[@R56]                  KL scale                                 TC≥200 mg/dL and/or TG≥150 mg/dL                                            NPD in OA+ and OA--\                  47
                                                                                                                                                             Association of OA and dyslipidemia\   
                                                                                                                                                             MV in OA+ and OA--                    

  Zayed *et al*[@R40]                   ACR                                      --                                                                          MV in OA+ and OA--\                   56
                                                                                                                                                             Association of OA and dyslipidemia    

  Cheng *et al*[@R57]*\**               --                                       --                                                                          Association of OA and dyslipidemia    NA

  Davis *et al*[@R26]                   Rx                                       --                                                                          MV in OA+ and OA--\                   67
                                                                                                                                                             Association of OA and dyslipidemia    

  Han *et al*[@R27]                     History of OA by physician               HDL\<40 mg/dL in M,\<50 mg/dL in W; TG≥150 mg/dL                            MV in OA+ and OA--\                   84
                                                                                                                                                             Association of OA and dyslipidemia    

  Dahaghin *et al*[@R41]                KL≥2, ACR, Cq                            --                                                                          MV in OA+ and OA--\                   69
                                                                                                                                                             Association of OA and dyslipidemia    

  Haugen *et al*[@R42]                  KL≥2                                     --                                                                          NPS in OA+\                           84
                                                                                                                                                             MV in OA+                             

  Inoue *et al*[@R30]                   KL≥2                                     HDL\<40 mg/dL in M,\<50 mg/dL in W; TG≥150 mg/dL                            NPD in OA+ and OA--\                  69
                                                                                                                                                             Association of OA and dyslipidemia\   
                                                                                                                                                             MV in OA+ and OA--                    

  Cemeroglu *et al*[@R22]               ≥3 articulations with KL≥2               TC\>200 mg/dL LDL\>100 mg/dL HDL\<40 mg/dL TG\>150 mg/dL                    NPD in OA+ and OA--\                  59
                                                                                                                                                             MV in OA+ and OA--\                   
                                                                                                                                                             NPS in OA+ and OA--\                  
                                                                                                                                                             Association of OA and dyslipidemia    

  Meek *et al*[@R51]                    Codes                                    --                                                                          MV in OA+\                            78
                                                                                                                                                             NPS in OA+                            

  Al-Arfaj[@R31]                        KL≥2                                     TC≥220 mg/dL                                                                NPD in OA+ and OA--\                  50
                                                                                                                                                             Association of OA and dyslipidemia    

  Suri *et al*[@R48]                    Pathria and Weishaupt scale              TC≥240 mg/dL                                                                NPD in OA+ and OA--\                  72
                                                                                                                                                             Association of OA and dyslipidemia    

  Puenpatom *et al*[@R4]                Codes\                                   Codes or HDL\<40 mg/dL in M,\<50 mg/dL in W; or TG≥150 mg/dL                NPD in OA+ and OA--\                  69
                                        Rx\                                                                                                                  Association of OA and dyslipidemia    
                                        History of OA by physician                                                                                                                                 

  Hart *et al*[@R19]                    KL≥2                                     --                                                                          Association of OA and dyslipidemia    78

  Maddah *et al*[@R24]                  KL≥2                                     TC≥5 mmol/L and TG≥2 mmol/L and HDL≤1 mmol/L in M, ≤1.1 mmol/L in W         NPD in OA+ and OA--\                  72
                                                                                                                                                             Association of OA and dyslipidemia\   
                                                                                                                                                             MV in OA+ and OA--                    

  Engström *et al*[@R34]                Codes: arthroplasty for hip or knee OA   HDL\<1.03 mmol/L in M,\<1.29 mmol/L in W; TG≥1.7 mmol/L or statin therapy   NPD in OA+ and OA--\                  79
                                                                                                                                                             Association of OA and dyslipidemia    

  Yoshimura *et al*[@R3]                KL≥2                                     HDL≤40 mg/dL                                                                MV in OA+ and OA--\                   91
                                                                                                                                                             Association of OA and dyslipidemia    

  Nielen *et al*[@R54]                  Codes                                    Codes: hypercholesterolemia                                                 NPD in OA+ and OA--\                  81
                                                                                                                                                             NPS in OA+ and OA--                   

  Marshall *et al*[@R44]                KL scale                                 Codes                                                                       NPD in OA+\                           74
                                                                                                                                                             NPS in OA+                            

  Hussain *et al*[@R37]                 Joint replacement                        HDL\<1.03 mmol/L in M,\<1.29 mmol/L in W; HTG≥1.7 mmol/L                    NPD in OA+ and OA--\                  85
                                                                                                                                                             Association of OA and dyslipidemia    

  Sowers *et al*[@R21]                  KL≥2                                     HDL≤45 mg/dL or LDL\>160 mg/dL or TG\>200 mg/dL                             MV in OA+ and OA--\                   70
                                                                                                                                                             Association of OA and dyslipidemia    

  Massengale *et al*[@R46]              --                                       TC≥240 mg/dL                                                                NPD in OA+ and OA--                   78
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACR, American College of Rheumatology; Cq, clinical; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; KL, Kellgren and Lawrence; LDL, low-density lipoprotein; M, men; MV, mean values of lipid profile; NA, if the data were issued only from congress; ND, not defined; NPD, number of patients with dyslipidemia; NPS, number of patients with statin therapy; OA+, patients with osteoarthritis; OA--, patients without osteoarthritis; Rx, radiography; TC, total cholesterol; TG, triglycerides; W, women.

\*Data from a congress.

The median STROBE quality score was 69.1% (range 42%--91%). Nine articles had a STROBE quality score \<60% ([table 3](#T3){ref-type="table"}).

In total, 30 articles assessed the association of OA and dyslipidemia, 30 assessed the prevalence of dyslipidemia among patients with OA and 22 assessed mean lipid level values among patients with OA ([table 3](#T3){ref-type="table"}).

Patient characteristics {#s3b}
-----------------------

This study involved 306 044 patients. The mean age range was 39.0±4.7[@R16] to 77.5±9.0 years.[@R17] The mean proportion of females was 53.2% (range 40.6%[@R18] to 100%[@R19]). The localisation was the knee in 23 articles,[@R3] hand in 9,[@R15] generalised OA in 3,[@R25] hip in 3,[@R25] spine in 2[@R48] and shoulder in 1.[@R17] MetS was reported in nine articles,[@R4] the prevalence of MetS ranged from 5%[@R24] to 97.5%.[@R40] The prevalence of obesity ranged from 7.8%[@R51] to 100%[@R15] and BMI from 22.3±2.7[@R30] to 37.3±5.9 g/cm^2^.[@R40] Seven articles described the use of statin treatment **(t**able 3).

###### 

Characteristics of the population on the 48 included articles: number, age, gender, overweight proportion

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                 Sample size (N = number of total patients; n= number of patients with OA)   Mean age (years) in OA+ and OA-- patients   Gender in OA+ and OA-- patients (% of F)   Overweight proportion (%) or BMI (kg/m^2^) in OA+ and OA--
  -------------------------------------- --------------------------------------------------------------------------- ------------------------------------------- ------------------------------------------ ------------------------------------------------------------
  Stürmer *et al*[@R25]                  n=809                                                                       --                                          OA+: F: 62.3%                              --

  Racaza *et al*[@R65]                   n=859                                                                       OA+: 62.9                                   OA+: F: 74.5%                              --

  Erb *et al*[@R66]                      N=250\                                                                      OA+: 57.3±10.1                              OA+: F: 62.5%                              OA+: 30.9±7.6 kg/m^2^
                                         n=64                                                                                                                                                               

  Eymard *et al*[@R28]                   n=559                                                                       OA+: 62.8                                   OA+: F: 70.1%                              

  Shea *et al*[@R29]                     n=791                                                                       OA+: 74.25±4.5                              OA+: F: 62.3%                              OA+: 27.28 kg/m^2^

  Salamon *et al*[@R50]                  N=927\                                                                      --                                          OA+: F: 83.4%                              OA+: 29.5 kg/m^2^
                                         n=344                                                                                                                                                              

  Abourazzak *et al*[@R20]               n=130                                                                       OA+: 56.7±8.1                               OA+: F: 100%                               OA+: 32.54±2.9 kg/m^2^

  Juge *et al*[@R17] *\**                n=147                                                                       OA+ : 75.8±10                               OA+: F: 68.7%                              OA+: 27.2 kg/m^2^

  Rollefstad *et al*[@R23] *\**          N=626\                                                                      OA+: 64.1±8.6\                              OA+: F: 73.1%\                             --
                                         n=469                                                                       OA--: 63.3±9.3                              OA--: F: 58%                               

  Saunders *et al*[@R53] *\**            n=57                                                                        --                                          --                                         --

  Nuñez *et al*[@R32] *\**               n=260                                                                       OA+: 69.8±8                                 OA+: F: 79.2%                              --

  Shukurova *et al*[@R67] *\**           n=1243                                                                      OA+: 56.1±7.9                               --                                         OA+: 61.6% of OP

  Salaru *et al*[@R33] *\**              n=61                                                                        OA+: 64.9±2.7                               OA+: F: 77%                                OA+: 60.6% of OP

  Kemta Lekpa *et al*[@R35] *\**         n=148                                                                       OA+: 57±10.6                                OA+: F: 75%                                OA+: 53% of OP\
                                                                                                                                                                                                            30.8±5.6 kg/m^2^

  Niu *et al*[@R36] *\**                 n=1091                                                                      OA+: 62                                     OA+: F: 55.5%                              --

  Haugen *et al*[@R43] *\**              n=748                                                                       OA+: 58.1                                   --                                         OA+65.7% of OP

  Courties *et al*[@R45] *\**            n=869                                                                       OA+: 54±7                                   OA+: F : 72%                               --

  Gandhi *et al*[@R49]                   n=1502                                                                      OA+: 55.3±15.5                              OA+: F: 48.8%                              OA+: 27.3 kg/m^2^

  Laires *et al*[@R38] *\**              n=197                                                                       OA+: 67±8.6                                 OA+: F: 79.2%                              --

  Thelier--Deloison *et al*[@R15] *\**   n=112\                                                                      --                                          --                                         OA+: 100% of OP
                                         n=26                                                                                                                                                               

  Soran *et al*[@R16]                    N=66\                                                                       OA+: 40.9±2.5\                              OA+: F: 72.2%\                             OA+: 29.9±3.3 kg/m^2^\
                                         n=36                                                                        OA--: 39±4.7                                OA--: F : 66.7%                            OA--: 27.6±3.8 kg/m^2^

  Cheras *et al*[@R18]                   N=96\                                                                       OA+: 69±9\                                  OA+: F 40.9%\                              OA+: 25.8 kg/m^2^\
                                         n=44                                                                        OA--: 68±7                                  OA--: F 40.4%                              OA--: 24.8 kg/m~2~

  Mishra *et al*[@R39]                   N=100\                                                                      OA+: 49.1±1.4\                              OA+: M: F: 71.4%\                          OA+: 23.4±0.6 kg/m^2^\
                                         n=28                                                                        OA--: 49.6±1.3                              OA--: M: F: 69.4%                          OA--: 22.9±0.6 kg/m^2^

  Oliviero *et al*[@R52]                 N=77\                                                                       OA+: 54.7±11.5\                             OA+: F: 68.7%\                             --
                                         n=16                                                                        OA--: --                                    OA--: --                                   

  Addimanda *et al*[@R47]                N=753\                                                                      OA+: 68±8\                                  OA+: F: 92.8%\                             OA+: 25.1±3.8 kg/m^2^\
                                         n=446                                                                       OA--: 63.9±9                                OA-- : F : 97.4%                           OA--: 24.9±3.9 kg/m^2^

  Philbin *et al*[@R55]                  N=69\                                                                       OA+: 65.8±9.3\                              OA+: F: 56.5%\                             OA+: 31.2±5.9 kg/m^2^\
                                         n=46                                                                        OA--: 67.9±6.7                              OA--: F: 65.2%                             OA--: 24.6±3.2 kg/m^2^

  Irshad *et al*[@R56]                   N=100\                                                                      --                                          --                                         --
                                         n=50                                                                                                                                                               

  Zayed *et al*[@R40]                    N=80\                                                                       OA+: 43.5±3.7\                              OA+: F: 87.5%\                             OA+: 37.3±5.9 kg/m^2^\
                                         n=40                                                                        OA--: 44.4±3.9                              OA--: F: 87.5%                             OA--: 23.5±1.3 kg/m^2^

  Cheng *et al*[@R57] *\**               N=56 607\                                                                   **--**                                      --                                         --
                                         n=23 530                                                                                                                                                           

  Davis *et al*[@R26]                    N=3885\                                                                     --                                          --                                         --
                                         n=301                                                                                                                                                              

  Han *et al*[@R27]                      N=10 839\                                                                   OA+: 64.5±10.1\                             OA+: F: 84.8%\                             --
                                         n=270                                                                       OA--: 53.2±11                               OA--: F: 50%                               

  Dahaghin *et al*[@R41]                 n=3585                                                                      --                                          --                                         OA+26.3±3.5 kg/m^2^

  Haugen *et al*[@R42]                   N=1348\                                                                     --                                          --                                         --
                                         n=726                                                                                                                                                              

  Inoue *et al*[@R30]                    N=795\                                                                      OA+: 66.3\                                  OA+: F: 79.3%\                             OA+: 23.8 kg/m^2^\
                                         n=251                                                                       OA--: 55.5                                  OA--: F : 54.7%                            OA--: 22.8 kg/m^2^

  Cemeroglu *et al*[@R22]                N=61\                                                                       --                                          OA+: F: 100%\                              --
                                         n=39                                                                                                                    OA--: F: 100%                              

  Meek *et al*[@R51]                     N=858\                                                                      OA+: 59.2±11                                OA+: F: 79.1%                              --
                                         n=206                                                                                                                                                              

  Al-Arfaj[@R31]                         N=246\                                                                      --                                          --                                         --
                                         n=122                                                                                                                                                              

  Suri *et al*[@R48]                     N=441\                                                                      OA+: 57.8±10.6\                             OA+: F: 49%\                               --
                                         n=310                                                                       OA--: 46.7±9.7                              OA--: F: 39%                               

  Puenpatom *et al*[@R4]                 N=7714\                                                                     OA+: 69.6\                                  OA+: F: 61.3%\                             OA+: 66.9% of OP\
                                         n=975                                                                       OA--: 41.3                                  OA--: F: 51.3%                             OA--: 34.8% of OP

  Hart *et al*[@R19]                     N=979\                                                                      --                                          OA+: F: 100%                               
                                         n=118                                                                                                                                                              

  Maddah *et al*[@R24]                   N=625\                                                                      OA+: 61.2\                                  OA+: F: 89.8%\                             
                                         n=244                                                                       OA--: 48.0                                  OA--: F: 73.8%                             

  Engström *et al*[@R34]                 N=5194\                                                                     OA+: 59.9\                                  OA+: F: 66.5%\                             OA+: 27.9 kg/m^2^\
                                         n=209                                                                       OA--: 57.6                                  OA--: F: 58.4%                             OA--: 25.37 kg/m^2^

  Yoshimura *et al*[@R3]                 N=1690\                                                                     OA+: 67.3±8.2\                              OA+: F: 74.6%\                             OA+: 23.6±2.9 kg/m^2^\
                                         n=71                                                                        OA--: 58.2±11.8                             OA--: F: 58.6%                             OA--: 22.4±3.2 kg/m^2^

  Nielen *et al*[@R54]                   N=175 956 n=4040                                                            OA+: 69.8\                                  OA+: F: 68.7%\                             --
                                                                                                                     OA--: 51                                    OA--: F: 50.4%                             

  Marshall *et al*[@R44]                 N=1076\                                                                     OA+: 69.0                                   OA+: F: 80.4%                              --
                                         n=341                                                                                                                                                              

  Hussain *et al*[@R37]                  N=20 430\                                                                   OA+: 68.3±7.7\                              OA+ : F: 66.2\                             OA+: 76.8% of OP, 28.6±5.0 kg/m^2^\
                                         n=1222                                                                      OA--: 64.8±8.6                              OA--: F: 59.5%                             OA--: 62.6% of OP, 26.8±4.5 kg/m^2^

  Sowers *et al*[@R21]                   N=664\                                                                      OA+: 50±5\                                  OA+: F: 100%\                              OA+: 35.6±11.1 kg/m^2^\
                                         n=53                                                                        OA--: 47±8                                  OA--: F: 100%                              OA--: 27.3±8.4 kg/m^2^

  Massengale *et al*[@R46]               N=2477\                                                                     --                                          OA+: F: 58.2%\                             --
                                         n=466                                                                                                                   OA--: F: 46.6%                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data from a congress. BMI, body mass index; F, female; M, male; OA, osteoarthritis.

Prevalence of dyslipidemia among patients with and without OA ([table 4](#T4){ref-type="table"}) {#s3c}
------------------------------------------------------------------------------------------------

###### 

Main results of prevalence of dyslipidemia and mean lipid-level values in patients with osteoarthritis (OA) and non-OA patients

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                    Prevalence of dyslipidemia   Mean CT level (mg/dL)   Mean high-density lipoprotein level (mg/dL)   Mean low-density lipoprotein level (mg/dL)   Mean triglyceride level (mg/dL)
  ----------------- ---------------------------- ----------------------- --------------------------------------------- -------------------------------------------- ---------------------------------
  OA+ population    30.2%±0.7%\                  245±25.1\               54.4±8.9\                                     126.5±20.7\                                  137.3±80.3\
                    n=14 823\                    n=6037\                 n=5856\                                       n=656\                                       n=2406\
                    n=28                         n=14                    n=18                                          n=9                                          n=15

  OA-- population   8.0%±0.1%\                   233.1±17.5\             53.1±7.5\                                     136.9±15.9\                                  131±27.3\
                    n=196 168\                   n=3763\                 n=412\                                        n=451\                                       n=3460\
                    n=13                         n=3                     n=7                                           n=2                                          n=6
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The mean prevalence of dyslipidemia was 30.2%±0.6% among 14 843 patients with OA and 8.0%±0.1% among 1 96 168 without OA. The mean prevalence with knee OA was 27.6%±1.4%,[@R15] hand OA 37.6%±1.6%,[@R22] generalised OA 30.5%±3.9%,[@R25] hip OA 20%±2.1%[@R25] and symptomatic OA was 21%.[@R28]

Mean lipid-level values with and without OA ([table 4](#T4){ref-type="table"}) {#s3d}
------------------------------------------------------------------------------

The mean lipid-level values for patients with and without OA were for TC, 245±25.1 and 233.1±17.5 mg/dL; LDL, 126.5±20.7 and 136.9±15.9 mg/dL; HDL, 54.4±8.9 and 53.1±7.5 mg/dL; and TG, 137.3±80.3 and 131±27.3 mg/dL.

Association between dyslipidemia and OA {#s3e}
---------------------------------------

Overall, 30 articles indicated the presence or the absence of an association between OA and dyslipidemia; 21 (70%) showed a positive association between OA and dyslipidemia[@R3]; 12/18 articles (67%) with STROBE score \>60% found a positive association.[@R3] In addition, 4/7 articles[@R19] that reported an OR adjusted on age and BMI found a positive association. Among the three with negative association findings after adjustment, two had a STROBE score \>60%.[@R34]

Overall risk of dyslipidemia with OA: meta-analysis {#s3f}
---------------------------------------------------

Among 204 148 patients from 13 articles,[@R4] the overall OR was 1.98 (95% CI 1.43 to 2.75, p\<0.0001; I^2^=94%), evaluated by a random-effects model ([figure 2](#F2){ref-type="fig"}).

![Forest plot for dyslipidemia among patients with and without osteoarthritis (OA).](rmdopen-2017-000442f02){#F2}

Risk of dyslipidemia with OA: sensitivity analyses {#s3g}
--------------------------------------------------

To strengthen our results, we performed four sensitivity analyses. First, we removed the studies that did not use ACR criteria or Kellgren-Lawrence grading for OA diagnosis: among 2568 patients from the six remaining articles,[@R22] the risk of dyslipidemia was increased with than without OA (OR 2.64, 95% CI 2.14 to 3.26, p\<0.00001, I^2^=0%). Second, we excluded studies with a STROBE score \<60%: among 203 629 patients from the nine remaining articles,[@R4] the risk of dyslipidemia remained increased with than without OA (OR 1.63, 1.13 to 2.36, p=0.009, I^2^=95%). Third, we excluded studies that specified the use of statin treatment because the definition of dyslipidemia in these studies was based on only lipid values and did not account for statin treatment. Among 41 539 patients from the 10 remaining articles,[@R4] the risk of dyslipidemia remained increased with than without OA (overall OR 1.93, 1.42 to 2.61, p\<0.0001, I^2^=87%). Fourth, we pooled the results of the articles that reported an age-adjusted and BMI-adjusted OR. Among 31 764 patients, from the four articles,[@R31] there was no association between dyslipidemia and OA (OR 1.31, 95% CI 0.88 to 1.95, p\<0.0001, I^2^=83%).

Risk of dyslipidemia with OA: subgroup analyses {#s3h}
-----------------------------------------------

We performed a subgroup analysis by OA localisation. The increased risk of dyslipidemia with OA persisted with knee OA (among 26 805 patients, OR 2.27, 1.33 to 3.89, p*=*0003, I^2^=88%)[@R15] and hand OA (among 814 patients, OR 2.12, 1.46 to 3.07, p*\<*0.0001, I^2^=0%)[@R22] but not hip OA (among 24 934 patients, OR 0.86, 0.69 to 1.08, p=0.18, I^2^=0%).[@R34]

Discussion {#s4}
==========

We investigated the potential association between OA and dyslipidemia with a systematic review and meta-analysis and found a 30% prevalence of dyslipidemia with OA, which seems much higher than in the non-OA population (8.0%). Furthermore, the meta-analysis revealed an increased risk of dyslipidemia, by 1.98, with than without OA and was observed with knee as well as hand OA.

The mean prevalence of dyslipidemia in hand OA was 37.6%±1.6%, much higher than the mean prevalence of 30.2%±0.6% with OA overall. Moreover, the risk of dyslipidemia was increased twofold with hand OA (OR 2.12, 95% CI 1.46 to 3.07). These results again confirm the systemic metabolic component of hand OA, as recently reported in the NEO study.[@R58] The pathophysiological link between hand OA and MetS might be explained by the action of the adipose-tissue source of proinflammatory cytokines and the action of visceral fat.[@R58]

Hip OA, defined by joint replacement, was not associated with dyslipidemia possibly because of a selection bias of patients: cardiovascular comorbidities often associated with dyslipidemia might have restricted the indication for surgery due to the perioperative period. Furthermore, mechanical stress is more involved than metabolic stress in this joint.

For knee OA, the mean prevalence of dyslipidemia was 27.6%±1.4% and the association between knee OA and dyslipidemia was confirmed with increased risk of dyslipidemia (OR 2.27, 95% CI 1.33 to 3.89). The association between knee OA and MetS is sometimes conflicting. Han *et al*,[@R27] Inoue *et al*,[@R30] and Hussain *et al*[@R37] did not find any positive association possibly because of different OA definitions. A recent study showed that the most important risk factor of knee OA was mechanical stress (before and after adjustment for metabolic factors), which limits the identification of a systemic metabolic component in knee OA.

Our meta-analysis has some limitations. The heterogeneity between studies was high, probably because of differences in OA localisations, definition of OA and dyslipidemia, statin therapy could not have been taken into account, and types and quality of studies. Dyslipidemia referred to lipid abnormalities such as hypercholesterolemia, low HDL level, high LDL level or hypertriglyceridemia. Because of the different definitions of dyslipidemia, we chose to define dyslipidemia first by high LDL level, then low HDL level, then hypercholesterolemia and hypertriglyceridemia. To counteract this heterogeneity, we performed sensitivity analyses to check whether the association between OA and dyslipidemia persisted after removing studies with poor methodology and found that the association persisted in all sensitivity analyses. Moreover, the heterogeneity of the studies was assessed by the I² index and we adapted the method to its value. The results of the meta-analysis are not modified by removing the most heterogeneous studies (*data not shown*). We were not able to integrate confounding factors such as age, BMI, HTA, smoking and physical activity in the overall statistical analysis. Obesity is a major risk factor of development and progression of OA. Obesity increases the risk of OA of the weightbearing joints due to excessive mechanical stress but is also associated with dyslipidemia in MetS.[@R59] We identified seven articles accounting for confounding factors of dyslipidemia and OA: four showed a positive association after adjustment on age and BMI. However, when we meta-analysed the seven articles that reported an age-adjusted and BMI-adjusted OR, there was no association between dyslipidemia and OA, but raw data before adjustment on age and BMI are used. Finally, the impact of statin treatment could not be assessed because of the lack of data concerning its prescription. In fact, we have no details about statin use in dyslipidemic and non-dyslipidemic patients. However, Riddle *et al* did not find beneficial effect of statins on the structural progress at patients monitored for a knee osteoarthritis.[@R60]

In this funnel plot, the distribution of common values is not heterogeneous. Likewise, we can consider that there is no major publication bias in our meta-analysis.

We demonstrated an association between dyslipidemia and OA, but the pathophysiological explanation for the causal relationship has not been clearly defined. Experimental studies suggest the existence of lipid metabolism dysfunction in OA. Mice with altered HDL metabolism showed knee OA despite abnormal weight gain.[@R61] Gierman *et al* showed that dietary cholesterol intake increased spontaneous cartilage damage in mice.[@R62] High LDL levels promote synovial inflammation and ectopic bone formation in mouse OA models.[@R63] Oxidised-LDL (oxLDL) could be involved in the development and progression of OA by stimulating synovial cells (macrophages, synovial fibroblasts and endothelial cells) and chondrocytes. A treatment strategy that lowers the level of oxLDL could be interesting.[@R64]

In conclusion, this is the first systematic review and meta-analysis demonstrating an association between OA and dyslipidemia, which illustrates the role of metabolic disturbances beyond glucose metabolism in OA pathophysiology. Such a study emphasises the need to screen and manage cardiovascular comorbidities in patients with OA in clinical practice.
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